Literature DB >> 23962351

Bacterial septicaemia in prerecruit edible crabs, Cancer pagurus L.

A L Smith1, M M A Whitten, L Hirschle, E C Pope, E C Wootton, C L Vogan, A F Rowley.   

Abstract

Juvenile edible crabs, Cancer pagurus L., were surveyed from Mumbles Head and Oxwich Bay in South Wales, UK, and the number of heterotrophic bacteria and vibrios in the hemolymph was determined. The percentage of crabs with hemolymph containing bacteria was variable over the survey with higher numbers of animals affected in summer than in winter. Post-moult crabs contained significantly higher numbers of heterotrophic bacteria in the hemolymph than pre- and intermoult animals. Crabs with cuticular damage to the gills also had significantly higher numbers of bacteria in the hemolymph. Crabs were found to have a high prevalence of infection by the dinoflagellate, Hematodinium. Such animals had significantly fewer bacteria in the blood in comparison with Hematodinium-free animals. Of the 463 crabs surveyed, only 3 individuals had hemolymph containing 2000 + CFU mL(-1). Based on 16S rRNA gene sequences, two of these crabs contained a Vibrio pectenicida-like isolate, while the other had a mixed assemblage of vibrios. Although 59% of the crabs surveyed had culturable bacteria in the hemolymph, the majority only had small numbers (<2000 CFU mL(-1) ), suggesting that such infections may be of limited importance to the sustainability of the crab fishery in this region.
© 2013 John Wiley & Sons Ltd.

Entities:  

Keywords:  Cancer pagurus; Vibrio pectenicida; crustacean; vibrio; vibriosis

Mesh:

Year:  2013        PMID: 23962351     DOI: 10.1111/jfd.12163

Source DB:  PubMed          Journal:  J Fish Dis        ISSN: 0140-7775            Impact factor:   2.767


  1 in total

1.  How does the dinoflagellate parasite Hematodinium outsmart the immune system of its crustacean hosts?

Authors:  Andrew F Rowley; Amanda L Smith; Charlotte E Davies
Journal:  PLoS Pathog       Date:  2015-05-07       Impact factor: 6.823

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.